Imaging test for neuroblastoma using a PET scan with 18F-MFBG
Tests a PET scan tracer in children with neuroblastoma, a cancer.
Plain-language title generated from the registry record
Registry title: 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people up to 18 years old who are suspected to have neuroblastoma or are confirmed to have it. They will have an 18F-MFBG PET scan.
- Age
- 0 to 18 years old, with a legal guardian
- Sex
- All sexes can join
- Disease stage
- Neuroblastoma that is suspected or confirmed. No particular stage is named.
- Earlier treatment
- Cannot have received experimental drugs or devices within the past month.
Main reasons for not taking part
- Severe heart, brain, liver, kidney or blood-forming system disease
- Radiation exposure from other studies or medical care in the past year that brought the yearly dose above 50 mSv
- Experimental drugs or devices within the past month
- Any condition the study's main doctor thinks could cause harm in this trial
Read by machine on 12 November 2026.
Where in China
- The First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Xinhui Su, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Trial code
- NCT06852807
- Record updated
- 8 August 2025
- Original description
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.Read full original descriptionShow less
Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Inclusion: Age 0-18 years old, with legal guardian; Clinically suspected or confirmed patients with neuroblastoma; If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent.
Exclusion: Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv; Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month; Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases; Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.